CN103694163A - 作为钾通道调节剂的化合物 - Google Patents
作为钾通道调节剂的化合物 Download PDFInfo
- Publication number
- CN103694163A CN103694163A CN201210366122.3A CN201210366122A CN103694163A CN 103694163 A CN103694163 A CN 103694163A CN 201210366122 A CN201210366122 A CN 201210366122A CN 103694163 A CN103694163 A CN 103694163A
- Authority
- CN
- China
- Prior art keywords
- compound
- cycloalkyl
- group
- alkyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 Cc1nc(Cl)n*(C)c1[N+]([O-])=O Chemical compound Cc1nc(Cl)n*(C)c1[N+]([O-])=O 0.000 description 9
- YZTJYBJCZXZGCT-UHFFFAOYSA-N C(C1)NCCN1c1ccccc1 Chemical compound C(C1)NCCN1c1ccccc1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N C(CC1)CC11CCNCC1 Chemical compound C(CC1)CC11CCNCC1 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 description 1
- HXNOEHIMWZDRTK-UHFFFAOYSA-N C(CNC1)c2c1[s]cc2 Chemical compound C(CNC1)c2c1[s]cc2 HXNOEHIMWZDRTK-UHFFFAOYSA-N 0.000 description 1
- RGBWBVGQZFJTEO-UHFFFAOYSA-N C(CNCC1)C1c1ccncc1 Chemical compound C(CNCC1)C1c1ccncc1 RGBWBVGQZFJTEO-UHFFFAOYSA-N 0.000 description 1
- IRADRONEMSSJFZ-UHFFFAOYSA-N C1C(c2ccncc2)=CCNC1 Chemical compound C1C(c2ccncc2)=CCNC1 IRADRONEMSSJFZ-UHFFFAOYSA-N 0.000 description 1
- ACLBUJFZNPDIQN-UHFFFAOYSA-N C1C2NCC1c1ccccc21 Chemical compound C1C2NCC1c1ccccc21 ACLBUJFZNPDIQN-UHFFFAOYSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N C1c2ccccc2CNC1 Chemical compound C1c2ccccc2CNC1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- FPEAARFNXIWCTP-UHFFFAOYSA-N C1c2ncccc2CNC1 Chemical compound C1c2ncccc2CNC1 FPEAARFNXIWCTP-UHFFFAOYSA-N 0.000 description 1
- DNHDDKSJDTYJPP-UHFFFAOYSA-N CC(C(C)N=C(C=C1C)Cl)C1[N+]([O-])=O Chemical compound CC(C(C)N=C(C=C1C)Cl)C1[N+]([O-])=O DNHDDKSJDTYJPP-UHFFFAOYSA-N 0.000 description 1
- LINZZISWCNKFEM-UHFFFAOYSA-N CC(C)(C)CC(N)=O Chemical compound CC(C)(C)CC(N)=O LINZZISWCNKFEM-UHFFFAOYSA-N 0.000 description 1
- DLWJMVUBKHFLLJ-UHFFFAOYSA-N CC(C)(C)CC(Nc(c(C)c1)c(C)cc1-c1cc(cccc2)c2nc1)=O Chemical compound CC(C)(C)CC(Nc(c(C)c1)c(C)cc1-c1cc(cccc2)c2nc1)=O DLWJMVUBKHFLLJ-UHFFFAOYSA-N 0.000 description 1
- XEVJQEIJAXJBKV-UHFFFAOYSA-N CC(C)(C)CC(Nc(c(C)c1)c(C)cc1Br)=O Chemical compound CC(C)(C)CC(Nc(c(C)c1)c(C)cc1Br)=O XEVJQEIJAXJBKV-UHFFFAOYSA-N 0.000 description 1
- PKOZZXIKPIQDEY-UHFFFAOYSA-N CC(C)(C)CC(Nc(c(C)c1)c(C)cc1N(CC1)CCC1c1ccncc1)=O Chemical compound CC(C)(C)CC(Nc(c(C)c1)c(C)cc1N(CC1)CCC1c1ccncc1)=O PKOZZXIKPIQDEY-UHFFFAOYSA-N 0.000 description 1
- CHGOTOWWACVIEJ-UHFFFAOYSA-N CC(C)(C)CC(Nc(c(C)c1)c(C)cc1N1C(C2)c3ccccc3C2C1)=O Chemical compound CC(C)(C)CC(Nc(c(C)c1)c(C)cc1N1C(C2)c3ccccc3C2C1)=O CHGOTOWWACVIEJ-UHFFFAOYSA-N 0.000 description 1
- WDKHCAAPSUGCEP-UHFFFAOYSA-N CC(C)(C)CC(Nc1c(C)c(C)c(CN(CC2)CC(C=C)=C2C#CC)cc1C)=O Chemical compound CC(C)(C)CC(Nc1c(C)c(C)c(CN(CC2)CC(C=C)=C2C#CC)cc1C)=O WDKHCAAPSUGCEP-UHFFFAOYSA-N 0.000 description 1
- BVBKDGDXNJYXDS-UHFFFAOYSA-N CC(C)(C)CC(Nc1c(C)cc(CN2CCC3(CCCC3)CC2)cc1C)=O Chemical compound CC(C)(C)CC(Nc1c(C)cc(CN2CCC3(CCCC3)CC2)cc1C)=O BVBKDGDXNJYXDS-UHFFFAOYSA-N 0.000 description 1
- BNWDDIARITUASN-UHFFFAOYSA-N CC(C)(C)CC(Nc1c(C)cc(N(CC2)Cc3c2cc[s]3)nc1C)=O Chemical compound CC(C)(C)CC(Nc1c(C)cc(N(CC2)Cc3c2cc[s]3)nc1C)=O BNWDDIARITUASN-UHFFFAOYSA-N 0.000 description 1
- JAXAQKCNBCFVMH-UHFFFAOYSA-N CC(C1)C(C)C(C)=CC1C=O Chemical compound CC(C1)C(C)C(C)=CC1C=O JAXAQKCNBCFVMH-UHFFFAOYSA-N 0.000 description 1
- WDRADOBWSFHLDE-UHFFFAOYSA-N CC/N=C(/CN(CCC1)CC2C1=NC=CCC2)\N Chemical compound CC/N=C(/CN(CCC1)CC2C1=NC=CCC2)\N WDRADOBWSFHLDE-UHFFFAOYSA-N 0.000 description 1
- RUZPSFUHBCXGLY-VIFPVBQESA-N CCCN1[C@H](CN)CCCC1 Chemical compound CCCN1[C@H](CN)CCCC1 RUZPSFUHBCXGLY-VIFPVBQESA-N 0.000 description 1
- OMGZOHFJDXEXSS-ZRDIBKRKSA-N COC(C(C1)c(cccc2)c2/C1=N/O)=O Chemical compound COC(C(C1)c(cccc2)c2/C1=N/O)=O OMGZOHFJDXEXSS-ZRDIBKRKSA-N 0.000 description 1
- HFFSDUMJDBSQKA-UHFFFAOYSA-N COC(C(C1)c2ccccc2C1=O)=O Chemical compound COC(C(C1)c2ccccc2C1=O)=O HFFSDUMJDBSQKA-UHFFFAOYSA-N 0.000 description 1
- DQPNUENHXRFFML-UHFFFAOYSA-N Cc(cc(N(CC1)CC2=C1C=CS2C)nc1C)c1[N+]([O-])=O Chemical compound Cc(cc(N(CC1)CC2=C1C=CS2C)nc1C)c1[N+]([O-])=O DQPNUENHXRFFML-UHFFFAOYSA-N 0.000 description 1
- SAWKGGUIJIMIBD-UHFFFAOYSA-N Cc(cc(N(CC1)Cc2c1cc[s]2)nc1C)c1N Chemical compound Cc(cc(N(CC1)Cc2c1cc[s]2)nc1C)c1N SAWKGGUIJIMIBD-UHFFFAOYSA-N 0.000 description 1
- BEQXZSPFDNEEHI-LOACHALJSA-N Cc(cc(N(CCCN1[C@H]2C=CC1)C2C=C)nc1C)c1N Chemical compound Cc(cc(N(CCCN1[C@H]2C=CC1)C2C=C)nc1C)c1N BEQXZSPFDNEEHI-LOACHALJSA-N 0.000 description 1
- CEPGJIACGSUAMK-UHFFFAOYSA-N Cc1nc(C)nc(C)c1N Chemical compound Cc1nc(C)nc(C)c1N CEPGJIACGSUAMK-UHFFFAOYSA-N 0.000 description 1
- BZZOSWZYMHVVBT-UHFFFAOYSA-N NC(CC1C(O)=O)c2c1cccc2 Chemical compound NC(CC1C(O)=O)c2c1cccc2 BZZOSWZYMHVVBT-UHFFFAOYSA-N 0.000 description 1
- HDFKMLFDDYWABF-UHFFFAOYSA-N O=C(CC1c2ccccc2)OC1=O Chemical compound O=C(CC1c2ccccc2)OC1=O HDFKMLFDDYWABF-UHFFFAOYSA-N 0.000 description 1
- AYQSFOUTNUTKNL-UHFFFAOYSA-N O=C1NC2c3ccccc3C1C2 Chemical compound O=C1NC2c3ccccc3C1C2 AYQSFOUTNUTKNL-UHFFFAOYSA-N 0.000 description 1
- YGDICLRMNDWZAK-UHFFFAOYSA-N OB(c1cc(cccc2)c2nc1)O Chemical compound OB(c1cc(cccc2)c2nc1)O YGDICLRMNDWZAK-UHFFFAOYSA-N 0.000 description 1
- HXLJFMRZKCSTQD-UHFFFAOYSA-N OC(C(C1)c(cccc2)c2C1=O)=O Chemical compound OC(C(C1)c(cccc2)c2C1=O)=O HXLJFMRZKCSTQD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
Description
Claims (20)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810024836.3A CN108250128A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
CN201210366122.3A CN103694163A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
PCT/CN2013/079617 WO2014048165A1 (zh) | 2012-09-27 | 2013-07-18 | 作为钾通道调节剂的化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210366122.3A CN103694163A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810024836.3A Division CN108250128A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103694163A true CN103694163A (zh) | 2014-04-02 |
Family
ID=50355854
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210366122.3A Pending CN103694163A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
CN201810024836.3A Pending CN108250128A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810024836.3A Pending CN108250128A (zh) | 2012-09-27 | 2012-09-27 | 作为钾通道调节剂的化合物 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN103694163A (zh) |
WO (1) | WO2014048165A1 (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105884673A (zh) * | 2016-06-03 | 2016-08-24 | 温州大学 | 一种吲哚衍生物的合成方法 |
CN106431897A (zh) * | 2016-09-27 | 2017-02-22 | 宿迁科思化学有限公司 | 一种2,4,6‑三甲基苯乙酰氯的新合成工艺 |
CN108147994A (zh) * | 2017-12-19 | 2018-06-12 | 南京药石科技股份有限公司 | 一种6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂卓的关键中间体及制备方法 |
CN110452172A (zh) * | 2019-08-21 | 2019-11-15 | 爱斯特(成都)生物制药股份有限公司 | 一种苯并己内酰胺的合成方法 |
CN111954663A (zh) * | 2017-12-13 | 2020-11-17 | 赛弗卢尔生命科学公司 | 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物 |
CN112010808A (zh) * | 2019-05-31 | 2020-12-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用 |
CN113292479A (zh) * | 2021-05-27 | 2021-08-24 | 南京合巨药业有限公司 | 一种5-氮杂螺[2.4]庚烷及其盐的制备方法 |
CN114685349A (zh) * | 2020-12-28 | 2022-07-01 | 四川科瑞德制药股份有限公司 | 顺-外-二环[2.2.1]庚烷-2,3-二甲酰亚胺的制备方法 |
CN115010647A (zh) * | 2022-04-19 | 2022-09-06 | 浙江天宇药业股份有限公司 | 一种双环内酰胺类化合物的制备方法 |
WO2023064585A1 (en) * | 2021-10-14 | 2023-04-20 | Vanderbilt University | 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders |
WO2023125935A1 (zh) * | 2021-12-31 | 2023-07-06 | 上海翰森生物医药科技有限公司 | 苯并哌啶衍生物调节剂、其制备方法和应用 |
WO2023143388A1 (zh) * | 2022-01-25 | 2023-08-03 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的酰胺类化合物及其制备和应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214539A1 (en) | 2016-06-10 | 2017-12-14 | Scifluor Life Sciences, Inc. | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives |
CA3048376A1 (en) | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
CN110511220B (zh) * | 2018-05-22 | 2022-04-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用 |
CN110330507A (zh) * | 2019-05-21 | 2019-10-15 | 四川师范大学 | 噻吩并吡啶离子化合物及其制备方法 |
CN115724799A (zh) * | 2021-08-26 | 2023-03-03 | 杭州和正医药有限公司 | 一种钾通道调节剂、组合物及应用 |
JP7294734B2 (ja) | 2021-10-27 | 2023-06-20 | シャンハイ ジムン バイオファーマ,インコーポレーテッド | カリウムチャネル調節剤としての化合物ならびにその調製および応用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101056845A (zh) * | 2004-09-13 | 2007-10-17 | H·隆德贝克有限公司 | 取代的苯胺衍生物 |
CN101563085A (zh) * | 2006-08-23 | 2009-10-21 | 威朗国际制药公司 | 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物 |
CN101778848A (zh) * | 2007-08-01 | 2010-07-14 | 威朗国际制药公司 | 作为钾通道调节剂的二氮杂萘衍生物 |
CN101868451A (zh) * | 2007-06-13 | 2010-10-20 | 威朗国际制药公司 | 作为钾通道调节剂的4-(n-氮杂环烷基)苯胺的衍生物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101583608A (zh) * | 2007-02-02 | 2009-11-18 | 诺瓦提斯公司 | 色烯s1p1受体拮抗剂 |
AU2008298545B2 (en) * | 2007-09-14 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
PL2212283T3 (pl) * | 2007-10-17 | 2012-01-31 | Sanofi Sa | Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
-
2012
- 2012-09-27 CN CN201210366122.3A patent/CN103694163A/zh active Pending
- 2012-09-27 CN CN201810024836.3A patent/CN108250128A/zh active Pending
-
2013
- 2013-07-18 WO PCT/CN2013/079617 patent/WO2014048165A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101056845A (zh) * | 2004-09-13 | 2007-10-17 | H·隆德贝克有限公司 | 取代的苯胺衍生物 |
CN101563085A (zh) * | 2006-08-23 | 2009-10-21 | 威朗国际制药公司 | 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物 |
CN101868451A (zh) * | 2007-06-13 | 2010-10-20 | 威朗国际制药公司 | 作为钾通道调节剂的4-(n-氮杂环烷基)苯胺的衍生物 |
CN101778848A (zh) * | 2007-08-01 | 2010-07-14 | 威朗国际制药公司 | 作为钾通道调节剂的二氮杂萘衍生物 |
Non-Patent Citations (15)
Title |
---|
ACS: "RN:1347259-01-1", 《STN-REGISTRY数据库》 * |
ACS: "RN:1347388-20-8", 《STN-REGISTRY数据库》 * |
ACS: "RN:1347588-61-7", 《STN-REGISTRY数据库》 * |
ACS: "RN:1347601-71-1", 《STN-REGISTRY数据库》 * |
ACS: "RN:1347892-90-3", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348011-09-5", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348034-45-6", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348043-28-6", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348067-26-4", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348136-60-6", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348523-52-3", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348662-15-6", 《STN-REGISTRY数据库》 * |
ACS: "RN:1348992-74-4", 《STN-REGISTRY数据库》 * |
ACS: "RN:1349819-33-5", 《STN-REGISTRY数据库》 * |
ACS: "RN:1349887-19-9", 《STN-REGISTRY数据库》 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105884673B (zh) * | 2016-06-03 | 2018-05-11 | 温州大学 | 一种吲哚衍生物的合成方法 |
CN105884673A (zh) * | 2016-06-03 | 2016-08-24 | 温州大学 | 一种吲哚衍生物的合成方法 |
CN106431897B (zh) * | 2016-09-27 | 2019-06-04 | 宿迁科思化学有限公司 | 一种2,4,6-三甲基苯乙酰氯的新合成工艺 |
CN106431897A (zh) * | 2016-09-27 | 2017-02-22 | 宿迁科思化学有限公司 | 一种2,4,6‑三甲基苯乙酰氯的新合成工艺 |
JP2021506810A (ja) * | 2017-12-13 | 2021-02-22 | サイフルーア ライフ サイエンシズ インコーポレイテッド | フッ素化4−(置換アミノ)フェニルカルバメート誘導体 |
CN111954663A (zh) * | 2017-12-13 | 2020-11-17 | 赛弗卢尔生命科学公司 | 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物 |
CN108147994A (zh) * | 2017-12-19 | 2018-06-12 | 南京药石科技股份有限公司 | 一种6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂卓的关键中间体及制备方法 |
CN108147994B (zh) * | 2017-12-19 | 2021-02-26 | 南京药石科技股份有限公司 | 一种6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂卓的关键中间体及制备方法 |
CN112010808B (zh) * | 2019-05-31 | 2021-11-30 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用 |
CN112010808A (zh) * | 2019-05-31 | 2020-12-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用 |
CN110452172A (zh) * | 2019-08-21 | 2019-11-15 | 爱斯特(成都)生物制药股份有限公司 | 一种苯并己内酰胺的合成方法 |
CN114685349A (zh) * | 2020-12-28 | 2022-07-01 | 四川科瑞德制药股份有限公司 | 顺-外-二环[2.2.1]庚烷-2,3-二甲酰亚胺的制备方法 |
CN114685349B (zh) * | 2020-12-28 | 2023-10-24 | 四川科瑞德制药股份有限公司 | 顺-外-二环[2.2.1]庚烷-2,3-二甲酰亚胺的制备方法 |
CN113292479A (zh) * | 2021-05-27 | 2021-08-24 | 南京合巨药业有限公司 | 一种5-氮杂螺[2.4]庚烷及其盐的制备方法 |
WO2023064585A1 (en) * | 2021-10-14 | 2023-04-20 | Vanderbilt University | 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders |
WO2023125935A1 (zh) * | 2021-12-31 | 2023-07-06 | 上海翰森生物医药科技有限公司 | 苯并哌啶衍生物调节剂、其制备方法和应用 |
WO2023143388A1 (zh) * | 2022-01-25 | 2023-08-03 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的酰胺类化合物及其制备和应用 |
CN115010647A (zh) * | 2022-04-19 | 2022-09-06 | 浙江天宇药业股份有限公司 | 一种双环内酰胺类化合物的制备方法 |
CN115010647B (zh) * | 2022-04-19 | 2024-04-09 | 浙江天宇药业股份有限公司 | 一种双环内酰胺类化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108250128A (zh) | 2018-07-06 |
WO2014048165A1 (zh) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103694163A (zh) | 作为钾通道调节剂的化合物 | |
CN105085489B (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
CN101203489B (zh) | 羟吲哚衍生物 | |
CN102958918B (zh) | 新型烟酰胺衍生物或其盐 | |
CN106458974B (zh) | 作为smo抑制剂的喹啉衍生物 | |
KR101780784B1 (ko) | 2,3-이치환된 1-아실-4-아미노-1,2,3,4-테트라하이드로퀴놀린 유도체 및 이의 브로모도메인 억제제로서의 용도 | |
TWI647220B (zh) | 雜芳基化合物及其用途 | |
CN104370828B (zh) | 用作raf激酶抑制剂的嘧啶衍生物 | |
CA2846785C (en) | New dihydroquinoline-2-one derivatives | |
CN110078741B (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
CN100384852C (zh) | 作为糖原磷酸化酶抑制剂的杂环酰胺衍生物 | |
CN109422755A (zh) | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 | |
CN105307657A (zh) | 杂芳基化合物和其用途 | |
CN102482221B (zh) | 作为katii抑制剂的双环和三环化合物 | |
JPH08510759A (ja) | G−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式カルバメート化合物 | |
CN106061966A (zh) | 用作溴区结构域抑制剂的双环杂环衍生物 | |
CN102341398A (zh) | 磺酰化四氢吡咯并吡嗪及其作为药物的用途 | |
CN102083800A (zh) | 杂芳基化合物和其用途 | |
CN110494433A (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
CN107001278A (zh) | 四氢异喹啉衍生物 | |
KR20210022140A (ko) | 헤테로아릴 화합물 및 이의 용도 | |
CN108368086A (zh) | 可用于治疗自身免疫疾病的二吡唑基衍生物 | |
CN102770435A (zh) | 吡唑并嘧啶类化合物及其作为pde10 抑制剂的用途 | |
CN105294654A (zh) | Alk激酶抑制剂及其制备方法和应用 | |
CN108003161A (zh) | 神经营养因子酪氨酸激酶受体抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LI Free format text: FORMER OWNER: JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LIMITED Effective date: 20150722 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150722 Address after: 201321 Pudong New Area Furong Road, Shanghai, No. 118 Applicant after: Shanghai Simcere Pharmaceutical Co., Ltd. Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Applicant after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 201321 Pudong New Area Furong Road, Shanghai, No. 118 Applicant before: Shanghai Simcere Pharmaceutical Co., Ltd. Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160802 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 201321 Pudong New Area Furong Road, Shanghai, No. 118 Applicant before: Shanghai Simcere Pharmaceutical Co., Ltd. Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited Applicant before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140402 |